viewCreso Pharma Ltd

Creso Pharma commercial partner Pharma Dynamics launches Cannamics in South Africa

Creso is progressing its strategy to commercialise the CannaQIX® range, which is among its CBD products.

Creso Pharma Ltd - Creso Pharma commercial partner Pharma Dynamics launches Cannamics in South Africa
The product will be sold through pharmacy retailers across South Africa

Creso Pharma Ltd (ASX:CPH) (FRA:1X8) (OTCMKTS:COPHF) has launched CBD product cannaQIX®Regular under the brand name Cannamics in South Africa via its commercial partner Pharma Dynamics.

The product will be sold through independent and major pharmacy retail chains across the country.

Creso co-founder and CEO Dr Miri Halperin Wernli said: “We are very excited that Pharma Dynamics managed such a great launch of cannaQIX®Regular, Cannamics in South Africa, providing a strong basis to enter further countries in Africa.”

Leading pharmaceutical company

Pharma Dynamics, a subsidiary of Lupin Limited (NSE:LUPIN), is a leading pharmaceutical company in South Africa and is ranked the fifth biggest generic pharmaceutical company in the country.

Pharma Dynamics leads with high-quality generics at affordable prices and is well-known for its investments into innovative wellness programs towards holistic healthcare.

Its growing over-the-counter range includes cold and flu, allergy, heartburn, and immune booster products.

The organisation also has a significant prescription portfolio with cardiovascular and central nervous system products consistently prescribed and recommended by leading doctors and pharmacists countrywide.

User-friendly formulation

Cannamics has been developed to Good Manufacturing Practice standards and is produced in Switzerland by Creso’s partner, Swiss-based food, and pharma development company, Domaco, Dr. med Aufdermaur AG to the highest Swiss quality with a ‘Swiss Made’ label.

The standardised, user-friendly strength and formulation allows precise dosage control and the pastilles have a more palatable taste compared to oils, is glucose-free and contains no tetrahydrocannabinol (THC).

Commercialising CannaQIX®

Pharma Dynamics business development head Tommy Scott said: “In spite of COVID-19 lockdown we managed to launch Cannamics, which brings recognised benefits in these difficult times.

“We are excited to enter this new category with such a renowned partner in the CBD space ”.

The launch is the latest step in Creso’s strategy to commercialise its CannaQIX® product range, with the company recently signing an agreement with DHS to enter the Brazilian retail market and launch the product by the fourth quarter of 2020.

Quick facts: Creso Pharma Ltd

Price: - -

Market: ASX
Market Cap: -

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Creso Pharma Ltd named herein, including the promotion by the Company of Creso Pharma Ltd in any Content on the Site, the Company receives from...


Creso Pharma subsidiary Mernova granted sales license from Health Canada

Creso Pharma (ASX:CPH) subsidiary Mernova managing director Jack Yu and vice president Isaac Allen joined Steve Darling from Proactive to discuss the granting of their sales license from Health Canada and what it allows them to do. Isaac Allen tells Proactive they are gearing up sales...

on 11/6/20

2 min read